Invir.IO® based oncolytic virus TG6050, is armed with IL-12 and an anti-CTLA4 antibody. A Phase I trial (Delivir) recently started enrolling patients with advanced non-small cell lung cancer (NSCLC)
An experimental cancer-killing virus has been administered to a human patient for the first time, with hopes the testing will ultimately reveal evidence of a new means of successfully fighting cancer tumors in people s bodies.
Transgene to receive $8 million upfront option exercise payment Conference call today on December 15, 2021, at 6:00 p.m. CET (12:00 p.m. ET) in English (details at the end of the release) Regulatory
The Collaboration will evaluate Eureka’s anti-CD19 ARTEMIS® T-cell therapy in combination with Imugene’s CD19-expressing oncolytic virus onCARlytics in solid tumours
Potential to. | November 1, 2021